{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T14:39:55Z","timestamp":1770475195515,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T00:00:00Z","timestamp":1047340800000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2003,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Aim<\/jats:bold> : To compare the efficacy of esomeprazole, 20\u2003mg once daily, vs. lansoprazole, 15\u2003mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> : During the initial open healing phase, 1391 patients with endoscopically verified reflux oesophagitis and a history of heartburn, with or without acid regurgitation, received esomeprazole 40\u2003mg for 4\u20138\u2003weeks. Patients who were healed (identified by endoscopy at 4 or 8\u2003weeks) and symptom free were then randomized to receive 6\u2003months of treatment with esomeprazole, 20\u2003mg once daily, or lansoprazole, 15\u2003mg once daily.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> : Esomeprazole, 20\u2003mg once daily, maintained a significantly higher proportion of patients in remission than lansoprazole, 15\u2003mg once daily, over 6\u2003months [83% (95% CI, 80\u201386%) of esomeprazole recipients compared with 74% (95% CI, 70\u201378%) of lansoprazole recipients; <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001; life table estimates]. When data were analysed according to baseline Los Angeles grade classification, esomeprazole, 20\u2003mg once daily, achieved consistently higher remission rates across all grades of disease severity, whereas the efficacy of lansoprazole decreased to a greater extent with increasing severity of reflux oesophagitis.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> : Esomeprazole, 20\u2003mg once daily, is more effective than lansoprazole, 15\u2003mg once daily, in maintaining remission in patients with healed reflux oesophagitis.<\/jats:p>","DOI":"10.1046\/j.1365-2036.2003.01464.x","type":"journal-article","created":{"date-parts":[[2004,12,19]],"date-time":"2004-12-19T09:56:26Z","timestamp":1103450186000},"page":"333-341","source":"Crossref","is-referenced-by-count":87,"title":["Esomeprazole 20\u2003mg and lansoprazole 15\u2003mg in maintaining healed reflux oesophagitis: Metropole study results"],"prefix":"10.1111","volume":"17","author":[{"given":"K.","family":"Lauritsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Devi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u2010A.","family":"Bigard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Bayerd\u00f6rffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"M\u00f3zsik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kristj\u00e1nsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Vetvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"De Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Orive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lark\u00f6","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,3,11]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200911"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.4.481"},{"key":"e_1_2_13_4_2","first-page":"211","article-title":"Duodenal ulcer and gastroesophageal reflux disease today: long\u2010term therapy \u2014 a sideways glance","volume":"69","author":"Bardhan KD","year":"1996","journal-title":"Yale J Biol Med"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9178669"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00379.x"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80087-4"},{"key":"e_1_2_13_9_2","first-page":"66B","article-title":"Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview","volume":"11","author":"Chiba N","year":"1997","journal-title":"Can J Gastroenterol"},{"issue":"2","key":"e_1_2_13_10_2","first-page":"S1","article-title":"An evidence\u2010based appraisal of reflux disease management \u2014 The Genval Workshop Report","volume":"44","author":"Talley NJ","year":"1999","journal-title":"Gut"},{"key":"e_1_2_13_11_2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1155\/1998\/925346","article-title":"The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts","volume":"12","author":"Thomson AB","year":"1998","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_13_12_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/j.1572-0241.1999.1123_a.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"94","author":"DeVault KR","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00813.x"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)82149-6"},{"issue":"2","key":"e_1_2_13_15_2","first-page":"A22\u20103","article-title":"Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg","volume":"118","author":"Wilder\u2010Smith C","year":"2000","journal-title":"Gastroenterology"},{"key":"e_1_2_13_16_2","first-page":"A51(Abstract","article-title":"Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg","volume":"47","author":"Wilder\u2010Smith C","year":"2000","journal-title":"Gut"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(01)02875-1"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00856.x"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03600.x"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05532.x"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03443.x"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01024.x"},{"key":"e_1_2_13_23_2","first-page":"1","volume-title":"Guidance on the Use of Proton Pump Inhibitors (PPI) in the Treatment of Dyspepsia.","author":"National Institute for Clinical Excellence.","year":"2000"},{"key":"e_1_2_13_24_2","volume-title":"British National Formulary","year":"2002"},{"key":"e_1_2_13_25_2","unstructured":"TAP Pharmaceuticals IL USA.Lansoprazole Prescribing Information.Available fromhttp:\/\/www.tap.com."},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.172"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01128.x"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.14156000.x"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-10-199605150-00001"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.144320000.x"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262080-00004"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/bega.2000.0124"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011211"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-3-199408010-00001"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90749-8"},{"key":"e_1_2_13_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90532-0"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2003.01464.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2003.01464.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T15:33:22Z","timestamp":1697211202000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2003.01464.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["10.1046\/j.1365-2036.2003.01464.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01464.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2]]}}}